急性骨髓性白血病市場 - 按疾病（成粒細胞、粒單核細胞、早幼粒細胞）、治療（化療、標靶治療）、給藥途徑（口服、腸胃外）、終端使用者（醫院、診所、專科中心）和預測2024 - 2032

Acute Myeloid Leukemia Market - By Disease (Myeloblastic, Myelomonocytic, Promyelocytic), Treatment (Chemotherapy, Targeted Therapy), Route of Administration (Oral, Parenteral), End-user (Hospital, Clinic, Specialty Center) & Forecast 2024 - 2032

出版日期: 2024年01月31日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在監管部門批准用於治療該疾病的新藥和療法的推動下，全球急性骨髓性白血病市場規模從 2024 年到 2032 年將以 10.7% 的CAGR成長。治療方案的快速進步和持續的研發工作為患者提供了更有效、更有針對性的治療方法，以改善整體結果。隨著新治療選擇的出現，以及現有治療方法的最佳化以提高療效，急性髓系白血病 (AML) 行業將大力關注個人化醫療和創新治療，從而不斷擴大。例如，2022 年 12 月，FDA 批准了 IDH1 抑制劑 OLU [89]，用於治療復發或難治性 (R/R) AML。此次批准基於一項 1/2 期試驗，涉及先前未接受過 IDH1 抑制劑的 IDH1 突變 R/R AML 患者

急性髓系白血病市場分為疾病類型、治療類型、給藥途徑、最終用戶和地區。

根據疾病類型，到 2032 年，由於其盛行率佔 AML 病例的很大一部分，粒單核細胞白血病領域的行業規模將實現 11.6% 的CAGR。粒單核細胞白血病的特徵是同時存在骨髓細胞和單核細胞，需要針對性的治療方法。隨著對此亞型分子機制的了解取得進展，客製化療法正在開發中，進一步促進該細分市場的成長。

預計在 2024 年至 2032 年間，標靶治療類型細分市場的 AML 市場規模將達到 11.4% 的CAGR。這是由於標靶治療在治療AML 方面的功效和特異性，與傳統化療相比，其副作用通常較少。針對 FLT3、IDH1 和 IDH2 等特定突變的藥物越來越受到關注。標靶治療開發和個人化醫療方法的不斷進步，為患者提供有希望的治療選擇，也將推動該細分市場的擴張。

2024年至2032年，亞太地區急性髓性白血病市場的CAGR將達到12.3%。這一成長可歸因於AML患病率的不斷上升，特別是在中國和日本等國家，以及人口老齡化的加劇。醫療保健基礎設施的強勁進步正在擴大該地區獲得治療選擇的機會。隨著對個人化醫療和創新療法的日益關注，亞太地區將進一步成為急性髓性白血病產業的關鍵貢獻者。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 10 章：公司簡介

Astellas Pharma Inc.
Bristol Myers Squibb Company
Celgene Corporation
Daiichi Sankyo Company, Limited
Jazz Pharmaceuticals plc
Novartis AG
Otsuka Pharmaceutical Co., Ltd.
Partner Therapeutics, Inc.
Pfizer Inc.
Rigel Pharmaceuticals, Inc.

簡介目錄

Product Code: 7991

Global Acute Myeloid Leukemia Market size will grow at 10.7% CAGR from 2024 to 2032, propelled by regulatory approvals for novel drugs and therapies for the disease treatment. Rapid advancements in treatment options and the ongoing R&D efforts are providing patients with access to more effective and targeted therapies for improving the overall outcomes. With strong focus on personalized medicine and innovative treatments, the acute myeloid leukemia (AML) industry will expand as new therapeutic options emerge while the existing treatments are optimized for enhanced efficacy. For instance, in December 2022, the FDA granted approval for OLU [89], an IDH1 inhibitor, for the treatment of relapsed or refractory (R/R) AML. This approval is based on a phase 1/2 trial involving patients with IDH1-mutant R/R AML who had not previously received IDH1 inhibitors

The acute myeloid leukemia market is segmented into disease type, treatment type, route of administration, end-user, and region.

Based on disease type, the industry size from the myelomonocytic leukemia segment will achieve 11.6% CAGR up to 2032, driven by its prevalence as it accounts for a significant portion of AML cases. Myelomonocytic leukemia is characterized by the presence of both myeloid and monocytic cells, requiring targeted treatment approaches. With advancements in understanding the molecular mechanisms of this subtype, tailored therapies are being developed, further contributing to the segment growth.

AML market size from the targeted therapy treatment type segment will foresee an 11.4% CAGR between 2024 and 2032. This is due to the efficacy and specificity of targeted therapies in treating AML, which often have fewer side effects compared to traditional chemotherapy. Drugs targeting specific mutations like FLT3, IDH1, and IDH2 are gaining prominence. The ongoing advancements in targeted therapy development and personalized medicine approaches for offering promising treatment options for patients will also drive the segment expansion.

Asia Pacific acute myeloid leukemia market will register a 12.3% CAGR from 2024 to 2032. The growth can be attributed to the increasing prevalence of AML, particularly in countries like China and Japan along with the rising aging population. Robust advancements in healthcare infrastructure are expanding the access to treatment options across the region. With the growing focus on personalized medicine and innovative therapies, Asia Pacific will further emerge as a key contributor in the acute myeloid leukemia industry.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of acute myeloid leukemia
  - 3.2.1.2 Advancement in research and technology
  - 3.2.1.3 Surging government initiative and policy
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Lack of awareness and knowledge
  - 3.2.2.2 High cost associated with treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Myeloblastic leukemia
5.3 Myelomonocytic leukemia
5.4 Promyelocytic leukemia
5.5 Monocytic leukemia
5.6 Other leukemia types

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Chemotherapy
- 6.2.1 Anti-metabolites
- 6.2.2 Alkylating agents
- 6.2.3 Anthracycline drugs
- 6.2.4 Other chemotherapy types
6.3 Targeted therapy
6.4 Immunotherapy
6.5 Other treatment types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Parenteral
7.3 Oral

Chapter 8 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals & clinics
8.3 Specialty centers
8.4 Homecare settings
8.5 Ambulatory care centers

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 Rest of Middle East and Africa